Approval of the Commitment Plan Submitted by SYSMEX CORPORATION

公正取引委員会
Japan Fair Trade Commission

Overview of the Alleged Conduct

Tie-in Sales

Sysmex required hospitals and other medical institutions to use only its designated reagents when using specific blood coagulation analyzers (CN series) to measure “D-dimer” or “FDP,” even though r eagents from other manufacturers c ould also be used.

Sysmex conditioned its supply of specific blood coagulation analyzers on the purchase of its designated reagents.

Sysmex is a leading company in the blood coagulation analyzer market.



There is a risk that suppliers selling non-Sysmex reagents may be excluded from transactions with hospitals or that their opportunities to trade with hospitals may decrease.

Overview of the Commitment Plan

1. Confirmation of the discontinuation of the alleged conduct, etc.

2. Notifying hospitals, wholesalers, etc., and ensuring disseminated to employees, etc.

3. Refraining from engaging in similar conduct to the alleged conduct (five years) (This applies to all of Sysmex’s blood coagulation analyzers and reagents as well.)

4. Creating codes of conduct, disseminating them to employees, etc., and conducting periodic training and audits.

5. Establishing a contact point for handling inquiries from purchasing hospitals, etc., regarding conducts that potentially violate the Act.

6. Third party monitoring and reporting on each matter (five years)*

(Note) The item marked with an asterisk (*) is a measure based on the policy for more efficient and effective implementation of the commitment procedures, which was announced at the regular press conference of the Secretary General held on July 3, 2024.